New York City-based physician scientist Ann Marie Schmidt and Baltimore epidemiologist Elizabeth Selvin have been awarded the American Heart Association Merit Award, receiving $1 million each in funding over the next five years. Schmidt will study the role of white blood cells in diabetic complications, while Selvin will research wearable glucose monitors and their impact on cardiometabolic risk in people with diabetes. These studies aim to improve screening, diagnosis, and patient care for individuals with diabetes, a major risk factor for cardiovascular disease.

Approximately 3 million people in the U.S. face challenges living with bleeding disorders like hemophilia. Symptoms can include excessive bleeding and bruising. Seeking medical advice is crucial for diagnosis and treatment. Mikey White Jr., a competitive swimmer with hemophilia, is an inspiring example of managing the condition with bravery and balance. Additionally, the United Network for Organ Sharing (UNOS) has appointed Melina Davis and Mark Johnson as new board members, bringing their executive leadership experience to advocate for innovative solutions and enhance donor awareness within the organ donation and transplant system.

Palatin Technologies' Phase 2 study reveals that patients on the obesity drug bremelanotide in combination with tirzepatide achieved a 4.4 percent weight reduction, highlighting the synergistic effect of the two mechanisms. The company is also addressing the challenge of weight regain and advancing the development of new drug applications. With the obesity treatment market projected to reach $100 billion by 2030, Palatin is well-positioned in this rapidly expanding market.

San Francisco Dental Implants, a leading dental implant center, has released informative blog posts tackling concerns related to dental implant surgery. The posts cover topics such as the drawbacks of cheap implants, finding a skilled oral surgeon, and the benefits of dental implants for long-term tooth loss solutions.

Revolution Rehab in Grand Rapids offers tailored one-on-one care, led by Dr. Tyler Kinch, to help patients of all ages restore mobility and well-being. Specializing in post-surgical rehabilitation, sports injuries, and chronic pain management, the clinic utilizes evidence-based practices and emphasizes preventative care and patient education. With a welcoming atmosphere and supportive staff, Revolution Rehab is the go-to choice for comprehensive and compassionate physical therapy in Grand Rapids.

Creative Biolabs showcased their advanced CDMO solutions, GMP-certified plasmid production, and groundbreaking TIL therapy development at the Scientist Solution Vendor Event. They offer a wide range of services including stable cell line development and sterile filling. Additionally, they are organizing a gene therapy webinar and planning to participate in key industry events throughout 2025.

GeoVax Labs, Inc. shares its financial results for 2024 and provides updates on ongoing trials and clinical evaluations of its vaccine candidates. The company is preparing for Phase 2b trial of GEO-CM04S1, conducting clinical evaluations of GEO-MVA, and planning a Phase 2 trial of Gedeptin(R) for head and neck cancer treatment. Additionally, GeoVax will host a conference call to discuss these updates and financial results.

Memory Lane is a dedicated provider of personalized dementia care, creating a warm and nurturing environment for residents. With trained staff and a focus on dignity and family involvement, Memory Lane offers hope and support for families navigating the challenges of dementia.

Centre for Neuro Skills is expanding its services by opening a new clinic in Plano, Texas, to meet the high demand for treatment of traumatic and acquired brain injuries. The 20,000 square ft. facility will offer programs for vision, neurobehavior, cognitive retraining, and more, providing advanced care for inpatient, outpatient, and residential brain injury patients.

GeoVax Labs, a biotechnology company focused on developing immunotherapies and vaccines, will have its CEO present at the 37th Annual Roth Conference. The company will also host investor meetings and discuss its lead clinical programs in COVID-19 and oncology.